DOCSLIB.ORG

Corifollitropin Α Followed by Menotropin for Poor Ovarian Responders’ Trial (COMPORT): a Protocol of a Multicentre Randomised Trial

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Corifollitropin Α Followed by Menotropin for Poor Ovarian Responders’ Trial (COMPORT): a Protocol of a Multicentre Randomised Trial Open Access Protocol BMJ Open: first published as 10.1136/bmjopen-2013-002938 on 1 June 2013. Downloaded from Corifollitropin α followed by menotropin for poor ovarian responders’ trial (COMPORT): a protocol of a multicentre randomised trial Nikolaos P Polyzos,1 Michel Camus,1 Joaquin Llacer,2 Konstantinos Pantos,3 Herman Tournaye1 To cite: Polyzos NP, ABSTRACT ARTICLE SUMMARY Camus M, Llacer J, et al. Background: Poor response to ovarian stimulation α Corifollitropin followed by affects a significant proportion of infertile couples menotropin for poor ovarian Article focus undergoing in vitro fertilisation (IVF) treatment. responders’ trial (COMPORT): ▪ Recently, the European Society of Human a protocol of a multicentre Recently, the European Society of Human Reproduction and Embryology (ESHRE) devel- randomised trial. BMJ Open Reproduction and Embryology developed new criteria oped new criteria to define women with poor 2013;3:e002938. to define poor ovarian response, the so-called ovarian response after ovarian stimulation for in doi:10.1136/bmjopen-2013- Bologna criteria. Although preliminary studies in vitro fertilisation (IVF), ‘The Bologna criteria’. 002938 these patients demonstrated very low pregnancy ▪ Up to date no randomised trial has been pub- rates, a recent pilot study has shown promising lished to evaluate the effectiveness of ovarian ▸ Prepublication history for results in women <40 years old fulfilling the criteria, stimulation protocols in poor ovarian responders this paper is available online. after treatment with corifollitropin α followed by according to the new ESHRE definition. To view these files please highly purified menotropin (hpHMG) in a ▪ Although poor ovarian responders according to visit the journal online gonadotropin-releasing hormone (GnRH) antagonist the Bologna criteria have very low pregnancy (http://dx.doi.org/10.1136/ setting. Corifollitropin α followed by menotropin for rates after ovarian stimulation for IVF, recently a http://bmjopen.bmj.com/ bmjopen-2013-002938). poor ovarian responders’ trial (COMPORT) is a pilot study demonstrated that corifollitropin α randomised trial aiming to investigate whether this followed by highly purified menotropin (hpHMG) Received 23 March 2013 novel protocol is superior to treatment with may result in very promising pregnancy rates. Revised 17 April 2013 Accepted 3 May 2013 recombinant follicle-stimulating hormone (FSH) in an antagonist setting for young poor Key messages ▪ α responders. Corifollitropin followed by menotropin for poor ovarian responders’ trial will provide conclusive This final article is available Methods/design: COMPORT is a multicentre, open evidence regarding the superiority of a novel for use under the terms of label, phase III randomised trial using a parallel two- protocol with corifollitropin α followed by the Creative Commons arm design. 150 patients <40 years old fulfilling the on October 1, 2021 by guest. Protected copyright. hpHMG versus recombinant follicle-stimulating Attribution Non-Commercial ‘Bologna criteria’ will be randomised to corifollitropin hormone in a gonadotropin-releasing hormone 2.0 Licence; see α followed by hpHMG (group A) or recombinant FSH http://bmjopen.bmj.com antagonist setting for the treatment of young (group B) in a GnRH antagonist protocol for (<40 years old) poor ovarian responders accord- IVF/intracytoplasmic sperm injection (ICSI). The ing to the Bologna criteria. primary outcome is the ongoing pregnancy rate (defined as the presence of intrauterine gestational Strengths and limitations of this study 1 Centre for Reproductive sac with an embryonic pole demonstrating cardiac ▪ This is the first randomised study to examine the Medicine, Universitair activity at 9–10 weeks of gestation). Secondary efficacy of two stimulation protocols in poor Ziekenhuis Brussel, Vrije outcomes are clinical and biochemical pregnancy ovarian responders as described by the newly Universiteit Brussel, Brussels, rates and number of oocytes retrieved. Central developed ESHRE definition. Belgium randomisation will be performed using a computer- ▪ To ensure sufficient power, the study’s sample 2Instituto Bernabeu, Alicante, Spain generated list and allocation concealment will be size calculation was based on a previous pilot α 3Genesis Athens, Athens, secured with the use of sealed-opaque envelopes. study with the use of corifollitropin followed Greece A sample size of 150 women is essential to detect a by hpHMG in the antagonist setting. A sample difference of 19.5% in ongoing pregnancy rates size of 150 patients has 85% power to detect Corresponding to between group A (28%) and group B (8.5%) with a significant differences. Dr Nikolaos P Polyzos; power of 85% and a level of significance at 0.05 ▪ The study is focusing only in young poor [email protected], using a two-sided Fisher’s exact test. responders (<40 years). Women of advanced age nikolaos.polyzos@uzbrussel. (≥40 years) were not included in the study. be Polyzos NP, Camus M, Llacer J, et al. BMJ Open 2013;3:e002938. doi:10.1136/bmjopen-2013-002938 1 Corifollitropin α followed by menotropin for poor ovarian responders’ trial BMJ Open: first published as 10.1136/bmjopen-2013-002938 on 1 June 2013. Downloaded from INTRODUCTION demonstrated an ongoing pregnancy rate of 28% in According to the Human Fertilisation and Embryology women <40 years, strongly suggesting the conduction of Authority, live-birth rate per started cycle after in vitro a future randomised trial testing this novel treatment fertilisation (IVF) has increased fairly consistently from protocol.10 14% in 1991 to 24.5% in 2010.1 Nonetheless, despite this substantial increase in live-birth rates over the years, specific patient populations experience low-pregnancy SUMMARY: RATIONALE FOR COMPORT STUDY ‘ ’ rates due to their limited ovarian response after ovarian The recently developed Bologna criteria by The stimulation for IVF.2 Poor ovarian responders are women ESHRE working group on Poor Ovarian Response fi fi who fail to respond to ovarian stimulation treatment and De nition represent the rst realistic attempt by a scien- fi fi represent up to 20% of the population seeking fertility ti c community (ESHRE) to standardise the de nition advice.3 of poor ovarian response in a simple and reproducible Despite the numerous trials conducted in women with manner, and randomised trials are needed to test the poor ovarian response, pregnancy rates remain low, with pregnancy rates in this population. In combination with studies reporting a live-birth of less than 10% irrespect- the existing literature, our previous work indicates that fi ive of the treatment protocol used and the age of the (1) women ful lling these criteria have very low preg- patients.45Yet, a considerable limitation of all the ran- nancy rates, irrespective of age (2) current treatment domised trials up to date is the lack of a uniform defin- protocols demonstrate ongoing pregnancy rates that do α ition to describe poor ovarian responders. Up to 2011, not exceed 8.5% and (3) corifollitropin followed by among 47 randomised trials in women with poor hpHMG might increase ongoing pregnancy rates in fi ovarian response, 41 different definitions for poor young patients (<40 years old) ful lling the criteria. fi fi ovarian response were utilized6; surprisingly, no more These ndings provide a strong rationale for a de nitive α than three trials used the same definition, whereas even large randomised controlled trial. The corifollitropin ’ trials from the same group of investigators used different followed by menotropin for poor ovarian responders definitions among different trials.6 Thus, it appears that trial (COMPORT) study will provide conclusive evidence any effort to identify the most optimal treatment for regarding the superiority or not of this novel protocol α these women seems to be futile, simply due to the lack with corifollitropin followed by hpHMG for the treat- fi of a uniform definition to describe women failing to ment of young poor ovarian responders ful lling the respond to stimulation. Bologna criteria. Recently, the European Society of Human Reproduction and Embryology (ESHRE) developed a METHODS AND ANALYSIS new definition in order to select patients suitable for http://bmjopen.bmj.com/ Study design inclusion in future clinical trials as poor ovarian respon- The COMPORT is a multicentre, open label, phase III ders, the so-called Bologna criteria.7 However, a limited multicentre superiority randomised trial using a parallel number of studies has been published to date including group, two-arm design with 1:1 allocation ratio with a patients with poor ovarian response according to the primary endpoint ongoing pregnancy rates. Four partici- ‘Bologna criteria’, whereas no randomised trial is pub- pating centres in Europe will recruit women less than lished or ongoing for this population. 40 years who fulfil the Bologna criteria for poor ovarian Preliminary reports in ‘Bologna poor responders’ response. The COMPORT study will compare controlled highlight the limited prospects for these women. on October 1, 2021 by guest. Protected copyright. ovarian hyperstimulation for intracytoplasmic sperm injec- Natural cycle IVF has been shown to result in disap- tion (ICSI) with corifollitropin α followed by hpHMG pointingly low live-birth rates, regardless of patients’ versus recombinant follicle-stimulating hormone (rFSH), age8; ovarian stimulation with widely accepted treatment in a gonadotropin-releasing hormone antagonist setting. modalities,
Load more

Recommended publications
  • Gonadotropin Therapy in Assisted Reproduction: an Evolutionary Perspective from Biologics to Biotech
    REVIEW Gonadotropin therapy in assisted reproduction: an evolutionary perspective from biologics to biotech Roge´rio de Barros F. Lea˜ o, Sandro C. Esteves Andrology & Human Reproduction Clinic (ANDROFERT), Referral Center for Male Reproduction, Campinas/SP, Brazil. Gonadotropin therapy plays an integral role in ovarian stimulation for infertility treatments. Efforts have been made over the last century to improve gonadotropin preparations. Undoubtedly, current gonadotropins have better quality and safety profiles as well as clinical efficacy than earlier ones. A major achievement has been introducing recombinant technology in the manufacturing processes for follicle-stimulating hormone, luteinizing hormone, and human chorionic gonadotropin. Recombinant gonadotropins are purer than urine- derived gonadotropins, and incorporating vial filling by mass virtually eliminated batch-to-batch variations and enabled accurate dosing. Recombinant and fill-by-mass technologies have been the driving forces for launching of prefilled pen devices for more patient-friendly ovarian stimulation. The most recent developments include the fixed combination of follitropin alfa + lutropin alfa, long-acting FSH gonadotropin, and a new family of prefilled pen injector devices for administration of recombinant gonadotropins. The next step would be the production of orally bioactive molecules with selective follicle-stimulating hormone and luteinizing hormone activity. KEYWORDS: Gonadotropins; Ovulation Induction; Assisted Reproductive Techniques; Systematic Review.
    [Show full text]
  • Aromatase Inhibition Reduces the Dose of Gonadotropin Required for Controlled Ovarian Hyperstimulation Mohamed F
    Journal of the Society for Gynecologic Investigation http://rsx.sagepub.com Aromatase Inhibition Reduces the Dose of Gonadotropin Required for Controlled Ovarian Hyperstimulation Mohamed F. M. Mitwally and Robert F. Casper Journal of the Society for Gynecologic Investigation 2004; 11; 406 DOI: 10.1016/j.jsgi.2004.03.006 The online version of this article can be found at: http://rsx.sagepub.com/cgi/content/abstract/11/6/406 Published by: http://www.sagepublications.com On behalf of: Society for Gynecologic Investigation Additional services and information for Journal of the Society for Gynecologic Investigation can be found at: Email Alerts: http://rsx.sagepub.com/cgi/alerts Subscriptions: http://rsx.sagepub.com/subscriptions Reprints: http://www.sagepub.com/journalsReprints.nav Permissions: http://www.sagepub.com/journalsPermissions.nav Citations http://rsx.sagepub.com/cgi/content/refs/11/6/406 Downloaded from http://rsx.sagepub.com at Serials Records, University of Minnesota Libraries on December 2, 2008 Aromatase Inhibition Reduces the Dose of Gonadotropin Required for Controlled Ovarian Hyperstimulation Mohamed F. M. Mitwally, MD, and Robert F. Casper, MD OBJECTIVE: To compare the use of the aromatase inhibitor, letrozole, in conjunction with follicle- stimulating hormone (FSH) injection, and FSH alonefor controlled ovarian hyperstimulation (COH) in patients with polycystic ovarian syndrome (PCOS) or ovulatory infertility. METHODS: This nonrandomized study included two study groups: 26 patients with PCOS and 63 with ovulatory infertility (unexplained infertility [41 patients], malefactor infertility [17 patients], and endometriosis [5 patients]), who received letrozole in addition to FSH; and two control groups: 46 PCOS patients and 308 with ovulatory infertility (unexplained infertility [250patients], malefactor infertility [42 patients], and endometriosis [16 patients], who received FSH only.
    [Show full text]
  • Appendiks Til Marte Myhre Reigstad, Inger Kristin Larsen, Ritsa Storeng
    Appendiks til Marte Myhre Reigstad, Inger Kristin Larsen, Ritsa Storeng. Kreftrisiko hos mor og barn etter fertilitetsbehandling. Tidsskr Nor Legeforen 2018; 138. doi: 10.4045/tidsskr.17.1098. Dette appendikset er et tillegg til artikkelen og er ikke bearbeidet redaksjonelt. Ramme 1 Beskrivelse av søkestrengen Søket består av 3 deler; fertilitetsbehandling, risiko, kreft som er kombinert med AND. Det er søkt med kontrollerte emneord (MeSH eller EMTREE), ord i tittel/abstakt /forfatters nøkkelord, kombinert med OR, innenfor de tre delene. EMBASE: artificial insemination/ or embryo disposition/ or exp embryo transfer/ or fertilization in vitro/ or in vitro oocyte maturation/ or intracytoplasmic sperm injection/ or ovulation induction/ or in vitro oocyte maturation/ or intracytoplasmic sperm injection/ or ovulation induction/ or superovulation/ or chorionic gonadotropin/ or clomifene/ or clomifene citrate/ or corifollitropin alfa/ or follitropin/ or gonadotropin/ or human menopausal gonadotropin/ or recombinant chorionic gonadotropin/ or recombinant follitropin/ or recombinant follitropin plus recombinant luteinizing hormone/ or recombinant luteinizing hormone/ or urofollitropin/ or gonadorelin/ or (gonadotropin* or clomifene or clomiphene or corifollitropin* or follitropin* or recombinant luteinizing hormone or urofollitropin* or gonadorelin* or buserelin* or leuprolide or menotropin* or nafarelin* or (fertilization* adj3 vitro) or (fertilisation* adj3 vitro) or (fertilization* adj3 invitro) or (fertilisation* adj3 invitro) or ivf or intracytoplasmic
    [Show full text]
  • Pharmacy Prior Authorization Guideline
    Harvard Pilgrim Health Care – Pharmacy Prior Authorization Guideline Guideline Name Gonadotropins and Antigonadotropins: Bravelle (urofollitropin), Cetrotide (cetrorelix), chorionic gonadotropin, Ganirelix, Gonal-F (follitropin alfa), Follistim AQ (follitropin beta), Menopur (menotropin), Novarel (chorionic gonadotropin), Ovidrel (choriogonadotropin alfa), and Pregnyl (chorionic gonadotropin) 1 . Criteria Product Name: Bravelle, Cetrotide, generic chorionic gonadotropin, Ganirelix, Gonal-F, Gonal- F RFF, Menopur, Novarel, Ovidrel, Pregnyl Diagnosis Gonadotropin therapy for females with infertility** Approval Length As requested up to 7 Month(s)* Guideline Type Prior Authorization Approval Criteria 1 - Patient has been approved for infertility services through a Harvard Pilgrim Health Care (HPHC) medical authorization^ Notes ^ The approval duration for formulary infertility medications (authorized by HPHC Pharmacy Benefit) will be approved 1 month prior to the date of the medical infertility services authorization (authorized by HPHC Medical Benefit) plus an additional 6 months unless specified otherwise on PA request (for a total of up to 7 months). *For approvals: Please approve at GPI List Name HPHCMEDIVF. **Some plans EXCLUDE gonadotropin products for infertility and claims will reject as Plan Exclusion: Plan excludes meds for infertility. Product Name: Follistim AQ Diagnosis Gonadotropin therapy for females with infertility** Approval Length As requested up to 7 Month(s) Guideline Type Non-Formulary Approval Criteria 1 - Patient has
    [Show full text]
  • Gonadotropin‑Releasing Hormone Analogs: Understanding Advantages and Limitations
    Review Article Gonadotropin‑releasing hormone analogs: Understanding advantages and limitations ABSTRACT Pratap Kumar, Alok Sharma1 Pituitary stimulation with pulsatile gonadotropin‑releasing hormone (GnRH) analogs Department of Obstetrics and induces both follicle‑stimulating hormone (FSH) and luteinizing hormone (LH). Pituitary Gynecology, Kasturba Medical College, Manipal University, gonadotropin secretions are blocked upon desensitization when a continuous GnRH Manipal, Karnataka, stimulus is provided by means of an agonist or when the pituitary receptors are occupied 1Department of Obstetrician with a competitive antagonist. GnRH antagonists were not available originally; therefore, and Gynecologist, Deen Dayal prolonged daily injections of agonist with its desensitizing effect were used. Today, Upadhyaya Hospital, Shimla, Himachal Pradesh, India single‑ and multiple‑dose injectable antagonists are also available to block the LH surge and thus to cause desensitization. This review provides an overview of the use of GnRH analogs Address for correspondence: which is potent therapeutic agents that are considerably useful in a variety of clinical Dr. Pratap Kumar, indications from the past to the future with some limitations. These indications include Department of Obstetrics and Gynecology, Kasturba Medical management of endometriosis, uterine leiomyomas, hirsutism, dysfunctional uterine College, Manipal University, bleeding, premenstrual syndrome, assisted reproduction, and some hormone‑dependent Manipal ‑ 576 104, tumours, other than
    [Show full text]
  • Revision File
    King Saud University College of Medicine 2nd Year, Reproduction Block Revision File This work includes lectures from 2 to 10 and it Contains 72 MCQs .. Hope this work will help you to remember the important thing about each drug. Good Luck L2- Drugs Inducing ovulation Q1: an obese female patient come to the hospital and she is complaining from infertility with investigation we found high LH and blood glucose with low FSH and on ultrasound we found small cysts looks like necklace so we confirmed the diagnosis of Polycystic ovarian syndrome what are the drugs of choice in this case ? A) Clomiphene+ Pregnyl. B) Clomiphene+ Metformin. : C. : 4 C) Leuprolin+ Bromocreptine. Q D) Bromocreptine+ Menotropin. Q2: Which one of the following drug can be used in case of Female infertility diagnosed with breast cancer ? : B. B. : A) Clomiphene. 3 B) Bromocreptine C) Leuprolin. D) Tamoxifen. D. Q D. : 2 Q3:which one of these drugs can treat infertile woman with high level of prolactin hormone in her blood ? Q A) Tamoxifen. B) Bromocreptine. C) Leuprolin. B. B. : D) Clomiphene. 1 Q Q4:in case of Normogonadotrophic which one is the best choice ? A) Leuprolin. B) Metformin. C) Clomiphene. D) Bromocreptine. L2- Drugs Inducing ovulation Q5: A patient diagnosed with prostate cancer which one can be used in this case ? A) Continuous use of Leuprolin. B) Continuous use of GOSERELIN. C) Pulsatile use of Leuprolin. D) A+B. : D.: 8 Q6: Which one of the following sentence is correct about the administration of clomiphene ? A) Give 50 mg/d for 5 days from 5th day of the cycle to the 10th day.
    [Show full text]
  • Scientific Congress
    SCIENTIFIC CONGRESS ADVANCING REPRODUCTIVE MEDICINE BUILD HEALTHY FAMILIES OCTOBER 28 - NOVEMBER 1, 2017 INSIDE this program OPENING CEREMONY .......... 2 ASRM WELCOME. 3 COMMITTEES AND AWARDS ASRM SCIENTIFIC CONGRESS PLANNING COMMITTEES ........ 7 ASRM OFFICERS AND BOARD OF DIRECTORS .......... 7 ASRM COMMITTEES ............8,9 SOCIETY AWARDS ...........10-23 ASRM STAR AWARDS .........24-26 ASRM SERVICE MILESTONE AWARDS ......................26 DISCLOSURE STATEMENTS AND CONFLICT OF INTEREST POLICY .. 27 SCHEDULE-AT-A-GLANCE. .29-31 JOIN US FOR OUR DAILY SCHEDULE ...........32-40 CONTINUING EDUCATION/ Opening Ceremony CME SESSIONS CONTINUING MEDICAL EDUCATION / CONTINUING EDUCATION .....43-44 Monday, October 30th, 7:45 am – 8:45 am PRE-CONGRESS COURSES ...45-66 in the Henry B. Gonzalez Convention Center NEEDS ASSESSMENT AND Hemisfair Ballroom LEARNING OBJECTIVES. 67 ASRM 2017 CONGRESS GRID. 68 PLENARY SESSIONS .........69-74 Come hear ASRM President, Dr. Richard Paulson, discuss LECTURES .................75-77 the Society's accomplishments this year and plans for SYMPOSIA .................78-96 "Advancing Reproductive Medicine to Build Healthy Families." INTERACTIVE SESSIONS .....97-108 ADDITIONAL SESSIONS ....109-113 TRACKS .................114-126 Plenary 1 will immediately follow in the same room. SPEAKER INDEX ..........127-128 DISCLOSURES ............129-133 A complimentary continental breakfast will be available NON-CME EDUCATIONAL SESSIONS 7:00 am – 7:45 am TICKETED EVENTS .........135-138 in the ASRM 5K RUN INFORMATION .. 135 Hemisfair Ballroom Lobby EXPERT ENCOUNTERS ........ 136 ROUNDTABLE DISCUSSIONS 139-145 VIDEO SESSIONS ..........146-153 ABSTRACT REVIEW COMMITEES .............155-156 ORAL ABSTRACT PRESENTATIONS ..........157-192 POSTER ABSTRACT PRESENTATIONS ..........193-259 ABSTRACT TOPIC INDEX ...260-262 ABSTRACT AUTHOR INDEX .263-292 DISCLOSURES ............293-308 ASRM 2O17 SCIENTIFIC CONGRESS :: FINAL PROGRAM Congress attendees.
    [Show full text]
  • Assessment Report
    31 July 2013 EMA/CHMP/41467/2013 Committee for Medicinal Products for Human Use (CHMP) Assessment report Ovaleap International non-proprietary name: follitropin alfa Procedure No. EMEA/H/C/002608 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union Table of contents 1. Background information on the procedure .............................................. 8 1.1. Submission of the dossier ...................................................................................... 8 1.2. Manufacturers ...................................................................................................... 9 1.3. Steps taken for the assessment of the product ......................................................... 9 2. Scientific discussion .............................................................................. 10 2.1. Introduction....................................................................................................... 10 2.2. Quality aspects .................................................................................................. 12 2.2.1. Introduction .................................................................................................... 12 2.2.2. Active Substance ............................................................................................
    [Show full text]
  • HUMAN MENOPAUSAL GONADOTROPINS (HMG) Policy Number: PHARMACY 288.3 T2 Effective Date: November 1, 2017
    UnitedHealthcare® Oxford Clinical Policy HUMAN MENOPAUSAL GONADOTROPINS (HMG) Policy Number: PHARMACY 288.3 T2 Effective Date: November 1, 2017 Table of Contents Page Related Policy INSTRUCTIONS FOR USE .......................................... 1 Acquired Rare Disease Drug Therapy Exception CONDITIONS OF COVERAGE ...................................... 1 Process BENEFIT CONSIDERATIONS ...................................... 2 Infertility Diagnosis and Treatment COVERAGE RATIONALE ............................................. 2 U.S. FOOD AND DRUG ADMINISTRATION .................... 4 APPLICABLE CODES ................................................. 5 CLINICAL EVIDENCE ................................................. 5 REFERENCES ........................................................... 8 POLICY HISTORY/REVISION INFORMATION ................ 10 INSTRUCTIONS FOR USE This Clinical Policy provides assistance in interpreting Oxford benefit plans. Unless otherwise stated, Oxford policies do not apply to Medicare Advantage members. Oxford reserves the right, in its sole discretion, to modify its policies as necessary. This Clinical Policy is provided for informational purposes. It does not constitute medical advice. The term Oxford includes Oxford Health Plans, LLC and all of its subsidiaries as appropriate for these policies. When deciding coverage, the member specific benefit plan document must be referenced. The terms of the member specific benefit plan document [e.g., Certificate of Coverage (COC), Schedule of Benefits (SOB), and/or Summary
    [Show full text]
  • Bilaga Till Rapport 1 (96) Endometrios – Diagnostik, Behandling Och Bemötande / Endometriosis – Diagnosis, Treatment and Patients’ Experiences, Rapport 277 (2018)
    Bilaga till rapport 1 (96) Endometrios – diagnostik, behandling och bemötande / Endometriosis – diagnosis, treatment and patients’ experiences, rapport 277 (2018) Bilaga 3 Exkluderade studier Appendix 3 Excluded studies Diagnostik Referens Exklusionsorsak Aboulghar MM, Hegazy M, Saber W, Hamed A, El Sheikhah A. Three- Fel frågeställning dimensional ultrasound versus office hysteroscopy in assessment of pain and bleeding with intrauterine contraceptive device. Middle East Fertil Soc J 2011;16:121-4. Acar S, Millar E, Mitkova M, Mitkov V. Value of ultrasound shear wave Fel studiedesign elastography in the diagnosis of adenomyosis. Ultrasound 2016;24:205-13. Adams F, Short J. Trans-vaginal ultrasound in diagnosing adenomyosis.Aust Fel studiedesign N Z J Obstet Gynaecol 2016;56:28. Ahmadi F, Haghighi H. Three-dimensional ultrasound manifestations of Fel studiedesign adenomyosis. Iran J Reprod Med 2013;11:847-8. Akturk E, Dede M, Yenen MC, Kocyigit YK, Ergun A. Comparison of nine Fel population morphological scoring systems to detect ovarian malignancy. Eur J Gynaecol Oncol 2015;36:304-8. Alcázar JL, Galan MJ, Mínguez JA, García-Manero M. Transvaginal color Fel population Doppler sonography versus sonohysterography in the diagnosis of endometrial polyps. J Ultrasound Med 2004;23:743-748. Andreotti RF, Fleischer AC. The sonographic diagnosis of adenomyosis. Ultrasound Q 2005;21:167-70. Ascher SM, Agrawal R, Bis KG, Brown ED, Maximovich A, Markham SM, Fel studiedesign et al. Endometriosis: appearance and detection with conventional and contrast-enhanced fat-suppressed spin-echo techniques. J Magn Reson Imaging 1995;5:251-7. Atri M, Reinhold C, Bret PM, Mehio AR, Chapman WB. Adenomyosis: US Fel studiedesign features with histologic correlation in an in-vitro study.
    [Show full text]
  • Efficacy, Efficiency and Effectiveness of Gonadotropin Therapy for Infertility Treatment
    REVIEW Efficacy, efficiency and effectiveness of gonadotropin therapy for infertility treatment Sandro C. EstevesI I ANDROFERT, Centro de Referência para Reprodução Humana, Av. Dr. Heitor Penteado, 1464, Campinas 13075-460, SP, Brazil. Gonadotropin therapy is an essential element in infertility treatments involving assisted reproductive technology. In recent years there have been outstanding advances in the development of new gonadotropins, particularly with the production of gonadotropins using biotechnological resources. Recombinant gonadotropins have higher specific activity compared with urinary counterparts, thus allowing subcutaneous administration of minimal amounts of glycoprotein. As a result, recombinant formulations have a better safety profile despite an overall similarity in terms of efficacy for pregnancy, as reported in many randomized controlled trials and meta-analyses. Gonadotropins stimulate the ovaries to develop follicles and oocytes, which are the raw material for fertilization and embryo production. The resulting embryos are transferred (fresh or frozen-thawed) to achieve pregnancy. The efficiency of a gonadotropin should therefore measured by the amount of drug used, the number of oocytes/embryos produced, and the number of pregnancies achieved by transferring fresh and/or frozen-thawed embryos to the uterus (cumulative pregnancy). Comparisons between different gonadotropin preparations should also take into account other important quality indicators in reproductive medicine, such as safety and patient-centeredeness.
    [Show full text]
  • Specialty Guideline Management
    Reference number C14414-A SPECIALTY GUIDELINE MANAGEMENT North Carolina State Health Plan: Fertility Agents PROGRAM RATIONALE Client Requested: The intent of the criteria is to ensure that patients follow selection elements established by North Carolina State Health Plan’s Commercial Prior Authorization Approval policy. PRIOR AUTHORIZATION CRITERIA1 • Coverage is provided for female infertility treatment and in males for non-infertility indications. • Coverage is NOT provided for patients using fertility medication in conjunction with any type of Artificial Reproductive Technology (ART) procedure. ART procedures include In Vitro Fertilization (IVF), Gamete Intrafallopian Transfer (GIFT), Zygote Intrafallopian Transfer (ZIFT), Intracytoplasmic Sperm Injection (ICSI) and Intrauterine (IUI) or Artificial Insemination. COVERED FERTILITY AGENTS* Medication Generic Name Covered Indications Gonadotropins Follicle Stimulating Hormone (FSH) Follistim AQ† follitropin beta . Ovulation induction . Hypogonadotropic hypogonadism in males Gonal-F/ follitropin alfa . Ovulation induction Gonal-F RFF Pen . Hypogonadotropic hypogonadism in males Human Chorionic Gonadotropin (hCG) Novarel†, Pregnyl†, chorionic gonadotropin . Ovulation induction hcG (generic)† . Selected cases of hypogonadotropic hypogonadism in males (i.e., hypogonadism secondary to a pituitary deficiency) . Prepubertal cryptorchidism Ovidrel choriogonadotropin alfa . Ovulation induction . Selected cases of hypogonadotropic hypogonadism in males (i.e., hypogonadism secondary to a pituitary
    [Show full text]